A New Alzheimer’s Treatment

Melissa West-Kevan

---

You've probably heard of Lecanemab or its brand name, Leqembi, and you're curious about what it's all about.

There’s been a promising breakthrough in Alzheimer’s treatment. For people in the early stages of Alzheimer’s, Leqembi has shown the ability to clear amyloid proteins, which are toxic to brain cells. Amyloid buildup in the brain is one of the main causes of Alzheimer’s disease.

On July 24, 2023, the FDA fully approved Lecanemab as a treatment for Alzheimer’s. Studies have shown that it can slow cognitive and functional decline in people in the early stages of the disease. Research published in early 2023 in the New England Journal of Medicine revealed that Lecanemab reduced the amount of amyloid in the brain and helped patients experience a slower decline in memory and thinking abilities.

There are some safety concerns to be aware of. The main risk is brain bleeds, though these cases are rare and usually small, affecting mostly people with specific gene mutations. Other possible side effects include brain swelling and fluid buildup. People on blood thinners should be especially cautious.

With the potential benefits and risks in mind, now is the perfect time to have a thoughtful conversation with your doctor to explore if this groundbreaking treatment could be the right choice for you or your loved one.

Here are some helpful questions to ask your doctor:

• How has Leqembi been proven to help people with early-stage Alzheimer’s?

• Why is removing amyloid plaque from the brain important, and how does it prevent further buildup?

• What tests should I take to see if Leqembi is right for me?

For more information on Leqembi, check out the phase 2 study sponsored by the National Institutes of Health and Eisai, makers of Leqembi, at The AHEAD Study.

---

Resources: 

The New England Journal of Medicine • 860 Winter Street • Waltham, MA 02451 • USA 

2024 AHEAD 3-45